Teva Pharmaceutical Industries (TEVA) Return on Capital Employed (2009 - 2026)
Teva Pharmaceutical Industries (TEVA) posted quarterly Return on Capital Employed of 8.52% for Q1 2026, up 696.0% year-on-year from 1.07% in Q1 2025, and up 6.11% on a QoQ basis from 8.03% in Q4 2025.
Teva Pharmaceutical Industries (TEVA) Return on Capital Employed (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported Return on Capital Employed for 18 consecutive years, with 8.52% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed rose 696.0% year-over-year to 8.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.52% (up 696.0% YoY) and the FY2025 annual result came in at 8.11%, up 917.0% from the prior year.
- Return on Capital Employed advanced to 8.52% in Q1 2026 per TEVA's latest filing, from 8.03% in the prior quarter.
- Over the last five years, Return on Capital Employed for TEVA reached as high as 8.52% in Q1 2026 and fell as low as 6.72% in Q4 2022.
- A 5-year average of 0.59% and a median of 1.42% in 2023 frame the typical range for Return on Capital Employed.
- The largest YoY upside for Return on Capital Employed was 1042 bps in 2022 against a maximum downside of 1140 bps in 2022.
- Year by year, Return on Capital Employed stood at 6.72% in 2022, then surged by 121 bps to 1.42% in 2023, then sank by 177 bps to 1.09% in 2024, then soared by 835 bps to 8.03% in 2025, then rose by 6 bps to 8.52% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 8.52%, 8.03%, and 6.41% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 0.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.52% |
| Dec 31, 2025 | 8.03% |
| Sep 30, 2025 | 6.41% |
| Jun 30, 2025 | 3.26% |
| Mar 31, 2025 | 1.57% |
| Dec 31, 2024 | -1.09% |
| Sep 30, 2024 | 1.74% |
| Jun 30, 2024 | 3.02% |
| Mar 31, 2024 | 0.78% |
| Dec 31, 2023 | 1.42% |
| Sep 30, 2023 | -4.05% |
| Jun 30, 2023 | -3.76% |
| Mar 31, 2023 | -4.49% |
| Dec 31, 2022 | -6.72% |
| Sep 30, 2022 | -3.51% |
| Jun 30, 2022 | -2.76% |
| Mar 31, 2022 | 1.59% |
| Dec 31, 2021 | 4.67% |
| Sep 30, 2021 | 5.57% |
| Jun 30, 2021 | -8.02% |